New drug cocktail targets Hard-to-Treat gut cancers

NCT ID NCT07446270

Not yet recruiting Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a combination of tunlametinib and anti-EGFR antibodies (cetuximab β or nimotuzumab) in 90 adults with advanced colorectal or pancreatic cancers that have RAS mutations and have not responded to standard treatments. The goal is to see if the combo shrinks tumors and improves survival, while monitoring safety. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tunlametinib combined with cetuximab β or nimotuzumab
What this could lead to: If successful, this could offer a new treatment option for people with advanced colorectal or pancreatic cancers that have specific RAS mutations and have not responded to standard therapies.
What could go wrong: This is an early Phase 2 trial with only 90 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma exocrine pancreatic carcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT FOR ADVANCED COLORECTAL CANCER TREATMENT FOR ADVANCED PANCREATIC CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.